Variability of objective gait measures across the expanded disability status scale in people living with multiple sclerosis: A cross-sectional retrospective analysis.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 21 08 2021
revised: 14 01 2022
accepted: 29 01 2022
pubmed: 7 2 2022
medline: 8 4 2022
entrez: 6 2 2022
Statut: ppublish

Résumé

The Expanded Disability Status Scale (EDSS) is widely utilized in clinical trials and routine care to evaluate disease burden and progression among people with multiple sclerosis (pwMS). However, instrumental gait measures may be more suitable than EDSS to track walking disability in pwMS. In this cross-sectional study, we aimed to quantify the variability of spatiotemporal gait measures within homologous EDSS categories. A total of 205 pwMS (age=46.5[SD=10.5] years, 72.2% female, EDSS range=1.0-6.5) were studied in this retrospective analysis. Participants underwent walking assessments through the GAITRite system and the following spatiotemporal gait measures were recorded: gait speed, mean normalized velocity (MNV), base of support, stride length, step length, percentage of gait cycle spent in double support and single support, and functional ambulation profile. The EDSS was evaluated by a certified neurologist. All gait measures exhibited fair to very strong correlations with scores on the EDSS (-0.81≤ρ Spatiotemporal gait measures have great variability within homologous EDSS categories. The high percent variability of gait speed and MNV (up to more than 50%) suggests that walking ability varies substantially within and across disability levels. Therefore, in addition to the EDSS, more comprehensive (multidimensional), objective patient-centric metrics would be needed to accurately evaluate disability in pwMS.

Sections du résumé

BACKGROUND BACKGROUND
The Expanded Disability Status Scale (EDSS) is widely utilized in clinical trials and routine care to evaluate disease burden and progression among people with multiple sclerosis (pwMS). However, instrumental gait measures may be more suitable than EDSS to track walking disability in pwMS. In this cross-sectional study, we aimed to quantify the variability of spatiotemporal gait measures within homologous EDSS categories.
METHODS METHODS
A total of 205 pwMS (age=46.5[SD=10.5] years, 72.2% female, EDSS range=1.0-6.5) were studied in this retrospective analysis. Participants underwent walking assessments through the GAITRite system and the following spatiotemporal gait measures were recorded: gait speed, mean normalized velocity (MNV), base of support, stride length, step length, percentage of gait cycle spent in double support and single support, and functional ambulation profile. The EDSS was evaluated by a certified neurologist.
RESULTS RESULTS
All gait measures exhibited fair to very strong correlations with scores on the EDSS (-0.81≤ρ
CONCLUSION CONCLUSIONS
Spatiotemporal gait measures have great variability within homologous EDSS categories. The high percent variability of gait speed and MNV (up to more than 50%) suggests that walking ability varies substantially within and across disability levels. Therefore, in addition to the EDSS, more comprehensive (multidimensional), objective patient-centric metrics would be needed to accurately evaluate disability in pwMS.

Identifiants

pubmed: 35124304
pii: S2211-0348(22)00160-2
doi: 10.1016/j.msard.2022.103645
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103645

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Tobia Zanotto (T)

Mobility and Falls Laboratory, Department of Physical Therapy, Rehabilitation Science, and Athletic Training, University of Kansas Medical Center, Kansas City, KS, USA. Electronic address: tzanotto@kumc.edu.

Jacob J Sosnoff (JJ)

Mobility and Falls Laboratory, Department of Physical Therapy, Rehabilitation Science, and Athletic Training, University of Kansas Medical Center, Kansas City, KS, USA. Electronic address: jsosnoff@kumc.edu.

Edward Ofori (E)

College of Health Solutions, Arizona State University, Phoenix, AZ, USA. Electronic address: edward.ofori@asu.edu.

Daniel Golan (D)

Department of Neurology and Multiple Sclerosis Center, Lady Davis Carmel Medical Center, Haifa, Israel; Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. Electronic address: golan.daniel@gmail.com.

Myassar Zarif (M)

South Shore Neurologic Associates, Patchogue, NY, USA. Electronic address: mzarif@southshoreneurologic.com.

Barbara Bumstead (B)

South Shore Neurologic Associates, Patchogue, NY, USA. Electronic address: bbumstea@southshoreneurologic.com.

Marijean Buhse (M)

South Shore Neurologic Associates, Patchogue, NY, USA. Electronic address: Marijean.buhse@stonybrook.edu.

Olivia Kaczmarek (O)

South Shore Neurologic Associates, Patchogue, NY, USA. Electronic address: okaczmarek@southshoreneurologic.com.

Jeffrey Wilken (J)

Washington Neuropsychology Research Group, Fairfax, VA, USA; Department of Neurology, Georgetown University, Washington, DC, USA. Electronic address: jwilken@neuropsychologyfairfax.com.

Lisa Muratori (L)

Department of Physical Therapy, Stony Brook University, Stony Brook, NY, USA. Electronic address: lisa.muratori@stonybrook.edu.

Thomas J Covey (TJ)

Division of Cognitive and Behavioral Neurosciences, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA; Neuroscience Program, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.. Electronic address: tjcovey@buffalo.edu.

Mark Gudesblatt (M)

South Shore Neurologic Associates, Patchogue, NY, USA. Electronic address: mgudesbl@southshoreneurologic.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH